We've changed the way you complete courses

In response to user feedback we have simplified the way courses can be completed.

Until now you needed to complete the topics and modules in order, from start to finish. But from today you can complete them in any order you wish.

Just visit any topic that interests you, and when you are ready mark it as completed by clicking the green 'Mark complete' button at the bottom of the page.

Once you have completed all of the topics in a module an assessment will be provided for you.

Complete all the assessments to finish the course.

Thanks, I've got it! X

Play the video to learn more
Pramlintide is an amylin analogue that has not been marketed in Europe for people with type 1 diabetes, but it is being used in the United States. And when looking at an overview of the different trials that have been done with pramlintide, you see that there is an advantage in HbA1c but there is a price to pay.

Pramlintide is an analogue of amylin, a peptide hormone released by beta cells along with insulin.

Select image for larger view

Qiao YC, Ling W, Pan YH, Chen YL, Zhou D, Huang YM, Zhang XX,, Zhao HL. Efficacy and safety of pramlintide injection adjunct to insulin therapy in patients with type 1 diabetes mellitus: a systematic review and meta-analysis. Oncotarget. 2017 8(39):66504-66515
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5630431/